Overview of Current Developments in Ketamine, Psychedelic Medicine in 2022

Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.

Pharmacy Times interviewed Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, on the implications of a survey that showed 65% of affected Americans want access to psychedelics for the treatment of mental health conditions.

Specifically, data have shown that patients with treatment-resistant anxiety, depression, and post-traumatic stress disorder are among those who would benefit from an expanded therapeutic regimen that includes psychedelic medicines, which have been found to be both effective and safe in the treatment of these conditions.

During the interview, Marques discussed some current developments in the ketamine and psychedelic medicine space that he is keeping his eye on in 2022, as well as what he sees for the future of ketamine and psychedelic medicines in the treatment of mental health and brain disorders.